Literature DB >> 33679782

Transcriptional Profiling of STAT1 Gain-of-Function Reveals Common and Mutation-Specific Fingerprints.

Simone Giovannozzi1,2, Jonas Demeulemeester3,4, Rik Schrijvers1, Rik Gijsbers2,5.   

Abstract

STAT1 gain-of-function (GOF) is a primary immunodeficiency typically characterized by chronic mucocutaneous candidiasis (CMC), recurrent respiratory infections, and autoimmunity. Less commonly, also immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX)-like syndromes with CMC, and combined immunodeficiency without CMC have been described. Recently, our group and others have shown that different mutation-specific mechanisms underlie STAT1 GOF in vitro, including faster nuclear accumulation (R274W), and reduced mobility (R321, N574I) to near immobility in the nucleus (T419R) upon IFNγ stimulation. In this work, we evaluated the transcriptomic fingerprint of the aforementioned STAT1 GOF mutants (R274W, R321S, T419R, and N574I) relative to STAT1 wild-type upon IFNγ stimulation in an otherwise isogenic cell model. The majority of genes up-regulated in wild-type STAT1 cells were significantly more up-regulated in cells expressing GOF mutants, except for T419R. In addition to the common interferon regulated genes (IRG), STAT1 GOF mutants up-regulated an additional set of genes, that were in part shared with other GOF mutants or mutation-specific. Overall, R274W and R321S transcriptomes clustered with STAT1 WT, while T419R and N574I had a more distinct fingerprint. We observed reduced frequency of canonical IFNγ activation site (GAS) sequences in promoters of genes up-regulated by all the STAT1 GOF mutants, suggesting loss of DNA binding specificity for the canonical GAS consensus. Interestingly, the T419R mutation, expected to directly increase the affinity for DNA, showed the most pronounced effects on the transcriptome. T419R STAT1 dysregulated more non-IRG than the other GOF mutants and fewer GAS or degenerate GAS promotor sequences could be found in the promoter regions of these genes. In conclusion, our work confirms hyperactivation of common sets of IFNγ-induced genes in STAT1 GOF with additional dysregulation of mutation-specific genes, in line with the earlier observed mutation-specific mechanisms. Binding to more degenerate GAS sequences is proposed as a mechanism toward transcriptional dysregulation in R274W, R321S, and N574I. For T419R, an increased interaction with the DNA is suggested to result in a broader and less GAS-specific response. Our work indicates that multiple routes leading to STAT1 GOF are associated with common and private transcriptomic fingerprints, which may contribute to the phenotypic variation observed in vivo.
Copyright © 2021 Giovannozzi, Demeulemeester, Schrijvers and Gijsbers.

Entities:  

Keywords:  STAT1; gain of function; gas; hypermorphic mutation; interferon gamma; mRNA sequencing; transcriptomic analysis

Year:  2021        PMID: 33679782      PMCID: PMC7925617          DOI: 10.3389/fimmu.2021.632997

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  44 in total

1.  Molecular mechanism and structural basis of gain-of-function of STAT1 caused by pathogenic R274Q mutation.

Authors:  Ryoji Fujiki; Atsushi Hijikata; Tsuyoshi Shirai; Satoshi Okada; Masao Kobayashi; Osamu Ohara
Journal:  J Biol Chem       Date:  2017-03-03       Impact factor: 5.157

2.  Novel STAT1 Gain-of-Function Mutation Presenting as Combined Immunodeficiency.

Authors:  Stella P Hartono; Alexander Vargas-Hernández; Mark J Ponsford; Ivan K Chinn; Stephen Jolles; Keith Wilson; Lisa R Forbes
Journal:  J Clin Immunol       Date:  2018-10-13       Impact factor: 8.317

3.  Identification of a distinct subset of disease-associated gain-of-function missense mutations in the STAT1 coiled-coil domain as system mutants.

Authors:  Jana Petersen; Julia Staab; Oliver Bader; Timo Buhl; Aleksandar Ivetic; Thomas Meyer
Journal:  Mol Immunol       Date:  2019-07-20       Impact factor: 4.407

Review 4.  Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.

Authors:  Christa S Zerbe; Beatriz E Marciano; Rohit K Katial; Carah B Santos; Nick Adamo; Amy P Hsu; Mary E Hanks; Dirk N Darnell; Martha M Quezado; Cathleen Frein; Lisa A Barnhart; Victoria L Anderson; Gulbu Uzel; Alexandra F Freeman; Andrea Lisco; Avindra Nath; Eugene O Major; Elizabeth P Sampaio; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-01-06       Impact factor: 9.079

5.  Distal regulatory element of the STAT1 gene potentially mediates positive feedback control of STAT1 expression.

Authors:  Katsutoshi Yuasa; Takao Hijikata
Journal:  Genes Cells       Date:  2015-11-23       Impact factor: 1.891

6.  Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.

Authors:  Kunihiko Moriya; Tasuku Suzuki; Nao Uchida; Tomohiro Nakano; Saori Katayama; Masahiro Irie; Takeshi Rikiishi; Hidetaka Niizuma; Satoshi Okada; Kohsuke Imai; Yoji Sasahara; Shigeo Kure
Journal:  Int J Hematol       Date:  2020-03-16       Impact factor: 2.490

7.  Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.

Authors:  Luyan Liu; Satoshi Okada; Xiao-Fei Kong; Alexandra Y Kreins; Sophie Cypowyj; Avinash Abhyankar; Julie Toubiana; Yuval Itan; Magali Audry; Patrick Nitschke; Cécile Masson; Beata Toth; Jérome Flatot; Mélanie Migaud; Maya Chrabieh; Tatiana Kochetkov; Alexandre Bolze; Alessandro Borghesi; Antoine Toulon; Julia Hiller; Stefanie Eyerich; Kilian Eyerich; Vera Gulácsy; Ludmyla Chernyshova; Viktor Chernyshov; Anastasia Bondarenko; Rosa María Cortés Grimaldo; Lizbeth Blancas-Galicia; Ileana Maria Madrigal Beas; Joachim Roesler; Klaus Magdorf; Dan Engelhard; Caroline Thumerelle; Pierre-Régis Burgel; Miriam Hoernes; Barbara Drexel; Reinhard Seger; Theresia Kusuma; Annette F Jansson; Julie Sawalle-Belohradsky; Bernd Belohradsky; Emmanuelle Jouanguy; Jacinta Bustamante; Mélanie Bué; Nathan Karin; Gizi Wildbaum; Christine Bodemer; Olivier Lortholary; Alain Fischer; Stéphane Blanche; Saleh Al-Muhsen; Janine Reichenbach; Masao Kobayashi; Francisco Espinosa Rosales; Carlos Torres Lozano; Sara Sebnem Kilic; Matias Oleastro; Amos Etzioni; Claudia Traidl-Hoffmann; Ellen D Renner; Laurent Abel; Capucine Picard; László Maródi; Stéphanie Boisson-Dupuis; Anne Puel; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2011-07-04       Impact factor: 14.307

8.  Properties of STAT1 and IRF1 enhancers and the influence of SNPs.

Authors:  Mohamed Abou El Hassan; Katherine Huang; Manoja B K Eswara; Zhaodong Xu; Tao Yu; Arthur Aubry; Zuyao Ni; Izzy Livne-Bar; Monika Sangwan; Mohamad Ahmad; Rod Bremner
Journal:  BMC Mol Biol       Date:  2017-03-09       Impact factor: 2.946

9.  A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation.

Authors:  Kornvalee Meesilpavikkai; Willem A Dik; Benjamin Schrijver; Nicole M A Nagtzaam; Angelique van Rijswijk; Gertjan J Driessen; Peter J van der Spek; P Martin van Hagen; Virgil A S H Dalm
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

10.  Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).

Authors:  Jie Zheng; Frank L van de Veerdonk; Katherine L Crossland; Sanne P Smeekens; Chun M Chan; Tariq Al Shehri; Mario Abinun; Andrew R Gennery; Jelena Mann; Dennis W Lendrem; Mihai G Netea; Andrew D Rowan; Desa Lilic
Journal:  Eur J Immunol       Date:  2015-09-01       Impact factor: 5.532

View more
  2 in total

1.  Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors.

Authors:  Emilie W Borgström; Marie Edvinsson; Lucía P Pérez; Anna C Norlin; Sara L Enoksson; Susanne Hansen; Anders Fasth; Vanda Friman; Olle Kämpe; Robert Månsson; Hernando Y Estupiñán; Qing Wang; Tan Ziyang; Tadepally Lakshmikanth; Carl Inge E Smith; Petter Brodin; Peter Bergman
Journal:  J Clin Immunol       Date:  2022-09-02       Impact factor: 8.542

2.  JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia.

Authors:  Jacob M Rosenberg; Joshua M Peters; Travis Hughes; Caleb A Lareau; Leif S Ludwig; Lucas R Massoth; Christina Austin-Tse; Heidi L Rehm; Bryan Bryson; Yi-Bin Chen; Aviv Regev; Alex K Shalek; Sarah M Fortune; David B Sykes
Journal:  Med (N Y)       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.